Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1000 of 5804
-
New hope for PSP: experimental drug LM11A-31 enters key trial
Disease control Not yet recruitingThe Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen B will evaluate the safety and efficacy of a single study drug, LM11A-…
Phase: PHASE2 • Sponsor: Adam Boxer • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
Disease control Not yet recruitingThe goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T\&E) can treat patients with diabetic macular edema (DME) who have not received prior treatment. It will a…
Phase: PHASE4 • Sponsor: The Third Peoples Hospital of Dalian • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a vaccine tame this rare brain disease?
Disease control Not yet recruitingThe Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen A will evaluate the safety and efficacy of a single study drug, AADva…
Phase: PHASE2 • Sponsor: Adam Boxer • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or destroy the tumor or circulating breast cancer stem cells if they show evidence of the SSTR2. 177Lu-D…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug aims to quiet chronic hives
Disease control Recruiting nowThis is a Phase IIa, randomized, blinded, placebo controlled,Multiple-Ascending Dose study of BBT001 in adult patients with Chronic Spontaneous Urticaria.
Phase: PHASE1, PHASE2 • Sponsor: Bambusa Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug duo aims to tackle tough lung cancer
Disease control Recruiting nowThis is a multicenter, open-label, phase II study to evaluate the safety, tolerability, clinical activity, and pharmacokinetics of ILKN421H in combination with pembrolizumab in participants with locally advanced or metastatic NSCLC. The study consists of 4 cohorts in participant…
Phase: PHASE2 • Sponsor: iLeukon Therapeutics, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug aims to tame eye inflammation in uveitis patients
Disease control Recruiting nowThis study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.
Phase: PHASE2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug duo takes on advanced lung cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with ivosidan (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.
Phase: PHASE1, PHASE2 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New Ultra-Long-Acting HIV shots could mean fewer doses for patients
Disease control Not yet recruitingThis study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
Phase: PHASE3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New PET scan may predict heart failure risk after heart attack
Knowledge-focused Not yet recruitingAcute myocardial infarction (AMI) initiates a complex myocardial repair process involving inflammation, fibroblast activation, and extracellular matrix remodeling, which may ultimately lead to adverse left ventricular remodeling and impaired cardiac function. Fibroblast activatio…
Sponsor: Ankara University • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
New Immune-Engaging drug takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThe goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study…
Phase: PHASE1 • Sponsor: TeneoSeven, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard …
Phase: PHASE1 • Sponsor: SHY Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New combo therapy aims to tame rare bleeding disorder
Disease control Recruiting nowThe purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New study aims to spare thousands of breast cancer patients from unnecessary chemo
Knowledge-focused Recruiting nowEndoPredict is a genomic signature used to determine the 10-year risk of recurrence in early HR+/HER2- breast cancers classified as of intermediate risk according to conventional clinical and pathological criteria, and to guide the adjuvant treatment decision: hormone therapy alo…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Could a simple ice water flush prevent pancreatitis after a common procedure?
Disease control Not yet recruitingEndoscopic retrograde cholangiopancreatography (ERCP) is an essential diagnostic and therapeutic tool used to manage diseases of the pancreatic and biliary systems. During the procedure, an upper endoscope is used to reach the major duodenal papilla, and a contrast material is in…
Phase: NA • Sponsor: Oman Ministry of Health • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Fat injections and lasers join forces to fight stubborn scars
Disease control ENROLLING_BY_INVITATIONPost-traumatic atrophic scars are characterized by skin depressions caused by loss of collagen and can lead to cosmetic and psychological concerns. Several treatment options have been proposed, including fractional carbon dioxide (CO2) laser resurfacing and autologous nanofat gra…
Phase: NA • Sponsor: Tanta University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a diabetes and cholesterol drug combo regrow hair?
Disease control Not yet recruitingAlopecia areata (AA) is a chronic immune disease characterized by non-scarring hair loss of the scalp or other hair-bearing areas Patients with AA frequently report high levels of dissatisfaction with commonly used treatment options due to ineffectiveness and adverse effects. The…
Phase: NA • Sponsor: Sohag University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Shorter surgery may be just as effective for treating achalasia
Disease control Not yet recruitingthis study is prospective , randomized and interventional ,will be performed on 50 patients to compare the clinical utility , safety profile and postoperative recovery metrics between short and long per-oral endoscopic myotomy , patients will be divided randomly into two equal gr…
Phase: NA • Sponsor: Assiut University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New vaccine aims to stop Virus-Linked cancers in organ transplant patients
⭐️ VACCINE ⭐️ Recruiting nowThis phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and related cancers in healthy volunteers and patients a…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 04, 2026 00:00 UTC
-
New injection could ease severe cancer bone pain
Symptom relief Not yet recruitingBackground: Cancer-induced bone pain (CIBP) is common in people with cancer. Bone cancer can also lead to anxiety, depression, and reduced mobility and quality of life. Researchers believe a research drug called resiniferatoxin (RTX) may be able to help. Objective: To learn wh…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC